AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

January 4, 2021 GMT

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

ADVERTISEMENT

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit  www.bellerophon.com.

Contacts    
At W2O Group:   At LifeSci Advisors:
Julie Normart   Brian Ritchie
(559) 974-3245   (212) 915-2578
jnormart@w2ogroup.com   britchie@lifesciadvisors.com